Context Therapeutics Inc. (CNTX)
NCM · Healthcare · Biotechnology
$1.39
-2.11%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$127.7M
Shares Outstanding
91.9M
Exchange
NCM
Currency
USD
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.8M | -10.6M | -13.8M | -9.3M |
| Net Income | -8.8M | -9.7M | -13.0M | -8.7M |
| Diluted EPS | $-0.09 | $-0.10 | $nan | $-0.09 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -14.9M | -25.1M | -29.9M | -39.7M |
| Net Income | -14.8M | -24.0M | -26.7M | -36.1M |
| Diluted EPS | $-0.93 | $-1.50 | $-0.46 | $-0.38 |